Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Macrogenics (MGNX)

Macrogenics (MGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,206,252
  • Shares Outstanding, K 61,107
  • Annual Sales, $ 104,880 K
  • Annual Income, $ -129,740 K
  • 60-Month Beta 2.23
  • Price/Sales 11.97
  • Price/Cash Flow N/A
  • Price/Book 4.31
Trade MGNX with:

Options Overview Details

View History
  • Implied Volatility 71.55%
  • Historical Volatility 115.99%
  • IV Percentile 2%
  • IV Rank 16.09%
  • IV High 148.61% on 09/15/21
  • IV Low 56.77% on 11/18/20
  • Put/Call Vol Ratio 0.12
  • Today's Volume 193
  • Volume Avg (30-Day) 486
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 4,796
  • Open Int (30-Day) 5,930

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.63
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.81
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.11 +3.30%
on 09/17/21
28.09 -29.73%
on 09/15/21
-3.54 (-15.21%)
since 08/24/21
3-Month
19.11 +3.30%
on 09/17/21
29.16 -32.30%
on 07/02/21
-6.37 (-24.40%)
since 06/24/21
52-Week
18.16 +8.70%
on 02/23/21
36.48 -45.89%
on 04/28/21
-4.95 (-20.05%)
since 09/24/20

Most Recent Stories

More News
Neuroblastoma Drugs Market Analysis By Growth, Emerging Trends, and Future Opportunities Till 2028

Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation...

CLRB : 0.9775 (-0.26%)
PFE : 43.94 (-0.57%)
LLY : 231.68 (-0.22%)
AZN.LN : 8,845.000 (+2.04%)
TEVA : 8.95 (-1.10%)
BMY : 60.23 (-0.66%)
MGNX : 19.74 (-3.89%)
JNJ : 164.36 (-0.30%)
Company News for Sep 17, 2021

Companies in The News Are: F,WYNN,LVS,MGNX

F : 13.78 (+0.51%)
LVS : 36.90 (-1.02%)
WYNN : 82.88 (-1.13%)
MGNX : 19.74 (-3.89%)
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028

Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation...

CLRB : 0.9775 (-0.26%)
PFE : 43.94 (-0.57%)
LLY : 231.68 (-0.22%)
AZN.LN : 8,845.000 (+2.04%)
TEVA : 8.95 (-1.10%)
BMY : 60.23 (-0.66%)
MGNX : 19.74 (-3.89%)
JNJ : 164.36 (-0.30%)
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

-- 21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A

MGNX : 19.74 (-3.89%)
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

-- Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved greater-than or equal to 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients...

MGNX : 19.74 (-3.89%)
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster...

MGNX : 19.74 (-3.89%)
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

MGNX : 19.74 (-3.89%)
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA(TM) in Patients with HER2-Positive Metastatic Breast Cancer

-- Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab

MGNX : 19.74 (-3.89%)
MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that...

MGNX : 19.74 (-3.89%)
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MGNX : 19.74 (-3.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics...

See More

Key Turning Points

3rd Resistance Point 21.64
2nd Resistance Point 21.25
1st Resistance Point 20.50
Last Price 19.74
1st Support Level 19.36
2nd Support Level 18.97
3rd Support Level 18.22

See More

52-Week High 36.48
Fibonacci 61.8% 29.48
Fibonacci 50% 27.32
Fibonacci 38.2% 25.16
Last Price 19.74
52-Week Low 18.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar